The European Commission has approved the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) as a first-line treatment for adults with advanced or inoperable hepatocellular carcinoma (HCC), the most common form of liver cancer. This decision follows the recommendation of the Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency (EMA). The Tecentriq-Avastin combination is now the first and only immunotherapy regimen approved in Europe for this patient group. “Tecentriq in combination with…
You must be logged in to read/download the full post.
The post Tecentriq-Avastin Combo Approved in Europe for Advanced or Inoperable Liver Cancer appeared first on BioNewsFeeds.